Home › Hereditary Sensory and Autonomic Neuropathies › District of Columbia › Washington
Hereditary Sensory and Autonomic Neuropathies clinical trials in Washington, DC
4 studies for Hereditary Sensory and Autonomic Neuropathies are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RecruitingPhase 1/2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
RecruitingPhase 2
- Washington DC VA Medical Center, Washington, DC, Washington D.C.
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
RecruitingPhase 2
- George Washington University Medical, Washington D.C.
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
RecruitingObservational study
- Johns Hopkins University, Washington D.C.
Hereditary Sensory and Autonomic Neuropathies trials in other cities
- San Antonio, TX7 studies
- Arlington, VA7 studies
- Boston, MA6 studies
- New York City, NY6 studies
- Nashville, TN6 studies
- Houston, TX5 studies
- Philadelphia, PA5 studies
- Portland, OR4 studies
- Pittsburgh, PA4 studies
- Ann Arbor, MI4 studies
- Los Angeles, CA3 studies
- Aurora, CO3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.